Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
The history of research compounds is a 90-year narrative of biochemical discovery, clinical application, regulatory evolution, and the emergence of entirely new compound classes. From the 1935 first synthesis of testosterone to the 2020s approval of triple GIP/GLP-1/glucagon agonists, each decade brought compounds that fundamentally changed our understanding of endocrinology, metabolism, and tissue biology. This timeline covers the key milestones.
1930s — The Testosterone Era Begins#
1931: Adolf Butenandt isolates androsterone from 15,000 liters of urine — the first isolation of a sex hormone in pure form. Butenandt receives the 1939 Nobel Prize in Chemistry.
1935: Ernst Laqueur's group at the University of Amsterdam isolates testosterone from bull testicular tissue and reports its structure in Nature. The same year, Butenandt and Leopold Ružička independently achieve the first chemical synthesis of testosterone from cholesterol.
1935 significance: The chemical synthesis of testosterone proved that the "testicular principle" responsible for masculinization was a defined organic molecule that could be produced without biological tissue — the foundation of all subsequent synthetic androgen research.
1937: Testosterone propionate becomes the first commercially available esterified testosterone — the ester concept (attaching a fatty acid chain to extend half-life) was established within two years of testosterone's isolation. The ester strategy remains the dominant formulation approach for injectable androgens 90 years later.
1940s–1950s — Ester Chemistry and Anabolic Optimization#
1950s: The "anabolic:androgenic ratio" concept emerges as researchers attempt to separate testosterone's muscle-building (anabolic) effects from its masculinizing (androgenic) effects. The Hershberger assay — measuring levator ani muscle (anabolic) vs. seminal vesicle/prostate (androgenic) weights in castrated rats — becomes the standard preclinical screening tool.
1954: Nandrolone (19-nortestosterone) is first synthesized. The removal of the 19-methyl group reduces androgenicity relative to anabolic activity — the first successful structural separation of anabolic from androgenic effects. Nandrolone's high anabolic:androgenic ratio (125:37) established the template for 19-nor compound design.
1959: Methandrostenolone (Dianabol) is synthesized by John Ziegler in collaboration with Ciba. Ziegler developed it specifically after observing Soviet athletes using testosterone at the 1954 World Weightlifting Championships. Dianabol's oral availability, rapid onset, and potent anabolism made it the defining compound of the early competitive athletics era.
Late 1950s: Oxandrolone, stanozolol, and boldenone are all synthesized during this period — the pharmaceutical industry's systematic SAR exploration of the androgen scaffold. Each structural modification was studied for effects on anabolic:androgenic ratio, oral bioavailability (17α-alkylation), half-life (ester modifications), and receptor binding affinity.
1960s–1970s — Growth Hormone and Peptide Beginnings#
1956: Human growth hormone (HGH) is first isolated from pituitary glands by Choh Hao Li and Herbert Evans. Early HGH research required extraction from cadaveric pituitary glands — a process that limited research supply and, tragically, was later linked to CJD transmission in some recipients.
1971: The structure of GnRH (gonadotropin-releasing hormone) is determined by Andrew Schally and Roger Guillemin's groups — work for which they shared the 1977 Nobel Prize in Physiology. This defined the top of the HPTA axis and opened the door to GnRH agonist/antagonist pharmacology.
1976: GHRH (growth hormone-releasing hormone) research advances significantly. Understanding the hypothalamic regulation of GH pulse secretion eventually led to the development of synthetic GHRH analogs, including CJC-1295.
1970s: Trenbolone is developed. Originally synthesized as a veterinary compound (Finaplix) for cattle weight gain, trenbolone's extremely high AR binding affinity and glucocorticoid receptor antagonism make it a pharmacologically unique research compound studied extensively in the following decades.
1980s — Recombinant Technology and Peptide Synthesis#
1985: Recombinant human growth hormone (rhGH) is approved — the first recombinant protein therapeutic approved by the FDA. The move from cadaveric HGH to recombinant somatropin eliminated CJD risk and enabled controlled research supply. This was a pivotal moment: peptide/protein compounds were now manufacturable at scale.
1982–1985: Solid-phase peptide synthesis (SPPS), developed by Bruce Merrifield (1984 Nobel Prize in Chemistry), becomes the standard method for synthetic peptide production. SPPS enables the assembly of custom peptide sequences on a resin support, one amino acid at a time — the technology that makes compounds like BPC-157, TB-500, and ipamorelin commercially feasible as research compounds.
1984: The first GHRP (GHRP-6) is identified. Cyril Bowers at Tulane discovers that a hexapeptide derived from met-enkephalin can stimulate GH release independently of GHRH — identifying what would later be characterized as the ghrelin/GHSR-1a system, years before ghrelin itself was discovered.
1980s: Estrogen receptor modulator research advances. Tamoxifen, originally synthesized in 1962, gains research prominence as its tissue-specific ER agonist/antagonist profile is characterized. The SERM concept (selective estrogen receptor modulator) is formalized.
1990s — Peptide Research Expansion and Ghrelin Discovery#
1991: BPC-157 (Body Protection Compound-157) is first described by Predrag Sikiric's group at the University of Zagreb. Derived from a sequence isolated from human gastric juice protein, BPC-157 demonstrates wound-healing, angiogenic, and gastroprotective effects in rodent models — initiating a research program that has now produced over 100 published studies.
1993: TB-500 (the synthetic version of thymosin beta-4) research expands significantly. Thymosin beta-4 had been isolated in 1965, but the 1990s saw systematic characterization of its actin-binding (G-actin sequestration), pro-migratory (cell migration stimulation), and angiogenic (VEGF upregulation) properties across multiple tissue types.
1999: Ghrelin is discovered by Masayasu Kojima's group in Japan — identified as the endogenous ligand for the orphan receptor GHSR-1a. This discovery retroactively explains GHRP-6's mechanism and inaugurates the ghrelin/GHSR-1a axis as a formal research target. Ipamorelin, a more selective GHSR-1a agonist than GHRP-6, is developed during this period.
1999: The first GLP-1 receptor agonist research compounds emerge. The GLP-1 hormone had been identified in 1983, but the 1990s characterization of its insulinotropic mechanism and appetite-suppressing central effects established GLP-1R as a key metabolic target.
Ipamorelin, €51 · 99.5% purity2000s — GLP-1 Agonists and Androgen Research Maturity#
2005: Exenatide (first GLP-1R agonist) receives FDA approval for type 2 diabetes. The clinical validation of the GLP-1 target opens the field to next-generation compounds with longer half-lives and higher receptor potency.
2005–2010: Aromatase inhibitor (AI) research matures. Anastrozole (1995 approval) and letrozole (1996 approval) are increasingly used as research tools for separating testosterone's direct AR effects from its aromatization-dependent E2 effects — enabling cleaner androgen mechanism studies.
2005: CJC-1295 is synthesized. The addition of drug affinity complex (DAC) technology extends GHRH analog half-life from minutes to days, enabling once-weekly dosing in research models and creating the sustained GHRH receptor stimulation paradigm.
2010s — Semaglutide and the Peptide Research Renaissance#
2012: Semaglutide development advances at Novo Nordisk. The key innovation over earlier GLP-1R agonists: fatty acid chain modification enabling once-weekly dosing (vs. twice-daily for exenatide) and oral bioavailability (achieved through SNAC technology in the oral formulation).
2017: Semaglutide injectable receives approval. The SUSTAIN trial program demonstrates unprecedented HbA1c reduction and, critically for research interest, significant body weight reduction — establishing the GLP-1 axis as a validated obesity research target.
2010s: NAD+ precursor research intensifies. David Sinclair's work at Harvard on sirtuins, SIRT1, and the role of NAD+ in aging biology creates substantial research interest in NMN and NR as interventions for the age-related NAD+ decline. SS-31 (elamipretide) research for mitochondrial dysfunction also expands significantly.
2019: Tirzepatide (dual GIP/GLP-1R agonist) enters Phase 2 trials. The dual agonist hypothesis — that targeting both GIP and GLP-1 receptors simultaneously would exceed either alone — begins to be validated in DIO rodent models and eventually in human trials.
2020s — Triple Agonists and the Modern Research Era#
2021: Tirzepatide Phase 3 SURMOUNT program demonstrates 20–22% body weight reduction — exceeding semaglutide's ~15% and establishing dual agonism as superior to mono-agonism for metabolic outcomes.
2022–2024: Retatrutide (triple GIP/GLP-1/glucagon agonist) Phase 2 data shows 24% body weight reduction at 48 weeks — the highest weight loss efficacy of any pharmacological agent studied to date. The addition of glucagon receptor agonism (increasing energy expenditure) to GLP-1/GIP (decreasing intake/improving insulin sensitivity) represents the frontier of metabolic research compound design.
2024–2026: Oral GLP-1R agonists (oral semaglutide, oral versions of other agonists) expand the research paradigm. Non-injectable delivery of large peptide molecules — historically limited to injection — becomes pharmacologically feasible through enteric absorption enhancers.
Present: Research compound diversity has never been greater. A modern research facility can access compounds spanning: synthetic peptides (SPPS-produced), recombinant proteins (fermentation-produced), small-molecule receptor agonists/antagonists, esterified androgens, selective receptor modulators, and oral GLP-1R agonists — each addressing distinct targets within the endocrine/metabolic research space.
Research Use Only. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · October 2026 · Category: Research Protocols & Science
